Nurexone Biologic EV/FCF

Que fait Nurexone Biologic ? Nurexone Biologic Inc, trading under the ticker NRX.V with ISIN CA67059R1091, is a company based in Edmonton, Canada. It operates in the pharmaceutical sector, focusing on the development of biological extracellular vesicles (EV)-based technology. The company has 8 employees and completed its IPO on May 8, 2012. Nurexone Biologic Inc is engaged in developing a platform for the production of exosome therapies, referred to as ExoTherapy. The company is working on a product called ExoPTEN, which is designed for the treatment of acute spinal cord injuries (SCI). The technology involves using exosomes, which are membrane-bound extracellular vesicles, to potentially reverse or reduce paralysis following spinal cord injury. The company's approach is subject to clinical trials and regulatory approvals, including potential FDA approval, before it can be applied to conditions such as spinal cord injuries, brain trauma injuries, and other neurological indications. Nurexone Biologic Inc maintains a website at https://nurexone.com/ for further information. The company's current status and future plans are based on the development and commercialization of its EV-based technology platform. Nurexone Biologic est l'une des entreprises les plus populaires sur Eulerpool.